Enlivex Therapeutics
ENLV
ENLV
7 hedge funds and large institutions have $8.3M invested in Enlivex Therapeutics in 2014 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
Holders
7
Holders Change
-2
Holders Change %
-22.22%
% of All Funds
0.19%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
2
Increased
2
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
VAM
1
Visium Asset Management
New York
|
$5.4M |
| 2 |
OC
2
Oppenheimer & Co
New York
|
$104K |
| 3 |
PWP
3
Private Wealth Partners
Mill Valley,
California
|
$86K |
| 4 |
TRCT
4
Tower Research Capital (TRC)
New York
|
$6K |
Top Sellers
| 1 |
SFM
1
Sphera Funds Management
Tel Aviv,
Israel
|
$0 |
| 2 |
SFM
2
Soros Fund Management
New York
|
$0 |
| 3 |
DA
3
DSC Advisors
Chicago,
Illinois
|
$547K |
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
VAM
1
Visium Asset Management
New York
| $5.4M | 844,160 | +217,160 | +35% |
|
|
KCM
2
Knoll Capital Management
Miami,
Florida
| $2.16M | 338,110 | – | – |
|
|
DA
3
DSC Advisors
Chicago,
Illinois
| $547K | 85,680 | -28,922 | -25% |
|
|
OC
4
Oppenheimer & Co
New York
| $104K | 16,299 | +16,299 | New |
|
|
PWP
5
Private Wealth Partners
Mill Valley,
California
| $86K | 13,500 | +13,500 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $6K | 871 | +571 | +190% |
|
|
SFM
7
Sphera Funds Management
Tel Aviv,
Israel
| – | – | -150,000 | Closed |
|
|
SFM
8
Soros Fund Management
New York
| – | – | -71,254 | Closed |
|
9
Morgan Stanley
New York
| $0 | 24 | – | – |
|